Ascendis Pharma A/S (NASDAQ:ASND) Given Consensus Rating of "Buy" by Analysts

Key Points

• Ascendis Pharma A/S has received a consensus rating of "Buy" from fifteen brokerages, with an average twelve-month price target of $244.36.
• The company reported earnings of ($0.93) per share for the last quarter, surpassing expectations of ($1.42) and achieving revenue of $216.28 million, which also exceeded analysts' forecasts.
• Recent institutional investments include significant stakes from firms like Soleus Capital Management and China Universal Asset Management, indicating growing interest in the company's stock.

Shares of Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) have been assigned an average recommendation of "Buy" from the fifteen brokerages that are presently covering the stock, Marketbeat.com reports. Fifteen research analysts have rated the stock with a buy recommendation. The average twelve-month price objective among analysts that have issued a report on the stock in the last year is $244.3571.

ASND has been the topic of a number of analyst reports. Wedbush lifted their target price on shares of Ascendis Pharma A/S from $212.00 to $220.00 and gave the stock an "outperform" rating in a research report on Friday, August 8th. Cantor Fitzgerald lifted their target price on shares of Ascendis Pharma A/S from $200.00 to $203.00 and gave the stock an "overweight" rating in a research report on Friday, August 8th. Wall Street Zen cut shares of Ascendis Pharma A/S from a "buy" rating to a "hold" rating in a research report on Friday, September 5th. Wells Fargo & Company reiterated an "overweight" rating and issued a $295.00 target price (up previously from $289.00) on shares of Ascendis Pharma A/S in a research report on Friday, August 8th. Finally, Morgan Stanley initiated coverage on shares of Ascendis Pharma A/S in a research report on Thursday, July 3rd. They issued an "overweight" rating and a $250.00 target price on the stock.

Ascendis Pharma A/S Stock Performance

Ascendis Pharma A/S stock opened at $194.62 on Tuesday. The firm's fifty day moving average price is $185.73 and its 200-day moving average price is $169.99. The stock has a market cap of $11.91 billion, a P/E ratio of -37.72 and a beta of 0.39. Ascendis Pharma A/S has a fifty-two week low of $118.03 and a fifty-two week high of $208.16.

Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) last posted its quarterly earnings data on Thursday, August 7th. The biotechnology company reported ($0.93) earnings per share for the quarter, beating the consensus estimate of ($1.42) by $0.49. The company had revenue of $216.28 million for the quarter, compared to analysts' expectations of $163.17 million. On average, analysts predict that Ascendis Pharma A/S will post -4.34 earnings per share for the current year.

Institutional Investors Weigh In On Ascendis Pharma A/S

A number of large investors have recently added to or reduced their stakes in the company. China Universal Asset Management Co. Ltd. grew its holdings in Ascendis Pharma A/S by 0.6% in the 2nd quarter. China Universal Asset Management Co. Ltd. now owns 12,186 shares of the biotechnology company's stock worth $2,103,000 after acquiring an additional 73 shares during the last quarter. Squarepoint Ops LLC bought a new stake in Ascendis Pharma A/S in the 2nd quarter worth $897,000. Headlands Technologies LLC bought a new stake in Ascendis Pharma A/S in the 2nd quarter worth $206,000. Soleus Capital Management L.P. grew its holdings in Ascendis Pharma A/S by 51.0% in the 2nd quarter. Soleus Capital Management L.P. now owns 85,000 shares of the biotechnology company's stock worth $14,671,000 after acquiring an additional 28,700 shares during the last quarter. Finally, Vestal Point Capital LP boosted its stake in shares of Ascendis Pharma A/S by 33.2% during the 2nd quarter. Vestal Point Capital LP now owns 200,000 shares of the biotechnology company's stock valued at $34,520,000 after purchasing an additional 49,858 shares in the last quarter.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.